Aura Biosciences (NASDAQ:AURA) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Aura Biosciences (NASDAQ:AURA) posted its quarterly earnings data on Monday. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.08, FiscalAI reports.

Aura Biosciences Stock Performance

Aura Biosciences stock opened at $6.56 on Monday. The stock has a market capitalization of $680.30 million, a price-to-earnings ratio of -3.75 and a beta of 0.41. Aura Biosciences has a 52-week low of $4.73 and a 52-week high of $9.53. The stock’s 50 day moving average price is $6.54 and its two-hundred day moving average price is $6.72.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Wall Street Zen lowered shares of Aura Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, October 12th. Finally, HC Wainwright lowered their price objective on Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Aura Biosciences has an average rating of “Hold” and an average price target of $17.50.

Aura Biosciences Company Profile

Aura Biosciences, Inc (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue.

Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer.